Medicines Transparency Alliance (MeTA) : country progress and key lessons

Wilbert Bannenberg Technical Director International MeTA Secretariat 30 May 2009, Amman, Jordan Medicines Transparency Alliance (MeTA): Country progress and key lessons MeTA 16/09/2008

What is MeTA?
An innovative and comprehensive approach
An international & national multi-stakeholder alliance designed to:
support country efforts to increase access to medicines across the whole supply chain
improve the flow of information and increase transparency on price, quality, availability and promotion
support stronger governance and accountability and share learning
16/09/2008 MeTA

MeTA Principles
Commitment to improving health
Comprehensive approach to health systems, including pharmaceuticals
Transparency and accountability can:
Improve system performance
Build confidence
Support equity and social justice
It takes us all working together to bring about the change we need
16/09/2008 MeTA

MeTa Country commitments
Establish an effective multi-stakeholder forum with public, private and civil society engagement
Progressive disclosure of data in four areas
Quality Regulatory, sourcing, quality assurance, vigilance
Availability Supply chain operations, equitable access
Price Supplier, wholesaler, retailer, import taxes, duties, affordability
Promotion Objective information, rational use, ethical advertising
16/09/2008 MeTA

MeTA Pilot Countries 16/09/2008 MeTA

MeTA Pilot objectives
Add value to country ATM efforts through transparency and multi-stakeholder working
Road test the MeTA approach in different country settings
Engage stakeholders at country and int’l levels
Provide a model for eventual roll out in further countries
16/09/2008 MeTA

MeTA implementation process Stakeholders engaged MeTA Council formed MeTA Secretariat formed Pre-MoU work done MoU signed Work started GHANA JORDAN KYRGYZSTAN PERU PHILIPPINES UGANDA ZAMBIA 16/09/2008 MeTA

Specific Success or Milestone 16/09/2008 GHANA JORDAN KYRGYZSTAN PERU PHILIPPINES UGANDA ZAMBIA Establishment of the physical secretariat Full support of government and private sector Identifying the stakeholders and approval of the work plan Sign MoU because it is final point Successful forums and especially the CSO Forum in Jan 2009 Successful launch and the receiving of funds Successful launch and media interest

Key Challenges to MeTA implementation
Stakeholder engagement and maintaining interest
Insufficient legislation/regulation and excessive bureaucracy
Difficulties in extracting information
Lack of tools for accessing information
16/09/2008 MeTA

Lessons learned in countries
Contexts are different in every country, so local conditions determine the pace and content of the work.
It takes time to get the right people at the table, build trust and develop a working relationship among stakeholders.
Consensus builds with a constant exchange of views.
Stakeholder commitment is key to a successful process.
Some problems in the medicines supply chain require tough political action to solve. Starting work on less controversial issues is key.
Systems and structures for disclosing data often do not exist in countries and may have to be created.
16/09/2008 MeTA

Key priorities for MeTA
Progressive disclosure of data about medicines
Developing and testing a new multi-stakeholder approach and preparing stakeholders for meaningful engagement
Ensuring the strong engagement of the private sector at country and international level
Increasing the voice of patients and consumers and strengthening capacity and opportunity for their engagement
Documenting innovation, change and good practice across the programme.
16/09/2008 MeTA

Congratulations to Jordan on the successful establishment and launch of MeTA and every good wish for the success of the programme here.
International Secretariat, [email_address]
www.MedicinesTransparency.org
16/09/2008 MeTA

Medicines Transparency Alliance (MeTA) : country progress and key lessons

by MeTApresents on Jun 08, 2009

Accessibility

Categories

Tags

Upload Details

Usage Rights

1 Embed 4

Statistics

Medicines Transparency Alliance (MeTA) : country progress and key lessons — Presentation Transcript